MLF2 and chronic myelogenous leukemia, BCR-ABL1 positive: MLF2 has been shown to interact with mutant huntingtin (HTT) protein and suppress HTT aggregation and toxicity.[28] In addition, MLF2 is a luminal component of the nuclear envelope blebs and can decrease the accumulation of phenylalanine–glycine repeat‐containing nucleoporins.[29, 30] Besides, MLF2 may act as an oncogenic factor in breast cancer and chronic myelogenous leukemia.[31, 32] However, it remains unknown how MLF2 contributes to tumorigenesis.